| 1.30 Data as of May 24 |  -0.034 / -2.56%Today’s Change | 0.90 Today|||52-Week Range 1.76 | +14.69% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $49.7M |
Company Description
NovaBay Pharmaceuticals Inc. is a clinical stage biotechnology company developing an anti-infective platform of compounds called the Aganocide compounds, for the treatment or prevention of infections in hospital and non-hospital environments. The company is developing commercial opportunities for its portfolio of anti-infectives Aganocide compounds in four healthcare markets: dermatology, ophthalmology, urology and hospital infections. It is also involved in developing NeutroPhase, a solution for cleansing and debriding wounds. The company was formerly known as NovaCal Pharmaceuticals, Inc. NovaBay Pharmaceuticals was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.
Employees
Shareholders
| Other institutional | 5.45% |
| Mutual fund holders | 2.86% |
| Individual stakeholders | 17.33% |
Top Executives
| Ramin Najafi, PhD | Chairman, President & Chief Executive Officer |
| Thomas J. Paulson, MBA | Chief Financial Officer, Secretary & Treasurer |
| Mark Brian Anderson, PhD | Chief Scientific Officer |
| Ken Krantz, MD, PhD | Vice President-Medical Affairs |
| Keith R. Bley, PhD | Senior Vice President-Product Development |
.
